Randy Maddux
Chief Operating Officer presso iBio CDMO LLC
Profilo
Randy J.
Maddux is currently the Chief Operating Officer at iBio CDMO LLC.
Previously, he held positions such as Director of Quality at Biogen, Assistant Director of Research & Development at Glaxo Wellcome Plc, Vice President & Site Director at GSK Plc, Director at The Life Sciences Foundation, and Vice President of Quality & Operations at Human Genome Sciences, Inc. He was also the Senior Vice President of Operations at Aptevo Therapeutics, Inc. from 2016 to 2018.
Maddux received his undergraduate degree from East Carolina University and his MBA from The Fuqua School of Business.
Posizioni attive di Randy Maddux
Società | Posizione | Inizio |
---|---|---|
iBio CDMO LLC
iBio CDMO LLC BiotechnologyHealth Technology Part of iBio, Inc., iBio CDMO LLC is a private company that is advancing its immuno-oncology pipeline of antibody therapeutic candidates against hard-to-drug tumor targets. The company is based in Bryan, TX. The company uses its patented discovery platform, which leverages artificial intelligence to consistently deliver antibody candidates against difficult targets. The company's lead candidate, IBIO-101, stimulates anti-tumor immunity by selectively depleting immunosuppressive TREG cells while sparing tumor cell killing T-Effector cells. iBio is pioneering the next generation of antibody therapeutics, leveraging its artificial intelligence-based and epitope steered antibody discovery platform. The company seeks to partner IBIO-400 to develop a safe and effective subunit vaccine capable of differentiating infected from vaccinated animals. The CEO of the company is Thomas F. Isett. | Chief Operating Officer | - |
Precedenti posizioni note di Randy Maddux
Società | Posizione | Fine |
---|---|---|
IBIO, INC. | Chief Operating Officer | 02/05/2022 |
GSK PLC | Corporate Officer/Principal | 01/06/2016 |
The Life Sciences Foundation
The Life Sciences Foundation Miscellaneous Commercial ServicesCommercial Services The Life Sciences Foundation engaged in education and biotechnology information dissemination. It collected and organized historical information to educate future innovators, to engage the general public, and to provide lay audiences with an understanding of life sciences and biotechnology. The company was founded by G. Steven Burrill, Dennis Gillings, John Lechleiter, Henri Termeer, and Arnold Thackray in 2010 and was headquartered in San Francisco, CA. | Director/Board Member | - |
APTEVO THERAPEUTICS INC. | Chief Operating Officer | - |
Glaxo Wellcome Plc | Corporate Officer/Principal | - |
Formazione di Randy Maddux
East Carolina University | Undergraduate Degree |
The Fuqua School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
BIOGEN INC. | Health Technology |
GSK PLC | Health Technology |
IBIO, INC. | Health Technology |
APTEVO THERAPEUTICS INC. | Health Technology |
Aziende private | 4 |
---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Glaxo Wellcome Plc | Health Technology |
The Life Sciences Foundation
The Life Sciences Foundation Miscellaneous Commercial ServicesCommercial Services The Life Sciences Foundation engaged in education and biotechnology information dissemination. It collected and organized historical information to educate future innovators, to engage the general public, and to provide lay audiences with an understanding of life sciences and biotechnology. The company was founded by G. Steven Burrill, Dennis Gillings, John Lechleiter, Henri Termeer, and Arnold Thackray in 2010 and was headquartered in San Francisco, CA. | Commercial Services |
iBio CDMO LLC
iBio CDMO LLC BiotechnologyHealth Technology Part of iBio, Inc., iBio CDMO LLC is a private company that is advancing its immuno-oncology pipeline of antibody therapeutic candidates against hard-to-drug tumor targets. The company is based in Bryan, TX. The company uses its patented discovery platform, which leverages artificial intelligence to consistently deliver antibody candidates against difficult targets. The company's lead candidate, IBIO-101, stimulates anti-tumor immunity by selectively depleting immunosuppressive TREG cells while sparing tumor cell killing T-Effector cells. iBio is pioneering the next generation of antibody therapeutics, leveraging its artificial intelligence-based and epitope steered antibody discovery platform. The company seeks to partner IBIO-400 to develop a safe and effective subunit vaccine capable of differentiating infected from vaccinated animals. The CEO of the company is Thomas F. Isett. | Health Technology |
- Borsa valori
- Insiders
- Randy Maddux